Valion Bio (VBIO) Change in Account Payables (2021 - 2025)
Valion Bio (VBIO) posted quarterly Change in Account Payables of -$201000.0 for Q4 2025, up 3.37% year-over-year from -$194455.8 in Q4 2024, and down 187.01% quarter-over-quarter from $231000.0 in Q3 2025.
Valion Bio (VBIO) Change in Account Payables (2021 - 2025) Analysis & Trends
Valion Bio's Change in Account Payables history runs 5 years deep, the most recent figure standing at -$201000.0 for Q4 2025.
- In Q4 2025, Change in Account Payables rose 3.37% year-over-year to -$201000.0; the TTM figure through Dec 2025 stood at $139000.0 (up 123.64% YoY), while the FY2025 annual figure was $139000.0, up 123.64% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$201000.0, down from $231000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.3 million in Q2 2022, with the low at -$510000.0 in Q4 2021.
- The 5-year median for Change in Account Payables is -$164500.0 (2022), against an average of -$5300.0.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables sank 377.33% in 2024, then jumped 304.42% in 2025.
- Valion Bio's Change in Account Payables stood at -$510000.0 in 2021, then surged by 45.29% to -$279000.0 in 2022, then surged by 126.88% to $75000.0 in 2023, then tumbled by 377.33% to -$208000.0 in 2024, then advanced by 3.37% to -$201000.0 in 2025.
- Business Quant data shows VBIO's Change in Account Payables at -$201000.0 in Q4 2025, $231000.0 in Q3 2025, and -$204000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -201,000.00 |
| Dec 31, 2025 | -201,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -204,000.00 |
| Jun 30, 2025 | -204,000.00 |
| Mar 31, 2025 | 313,000.00 |
| Mar 31, 2025 | 313,000.00 |
| Dec 31, 2024 | -208,000.00 |
| Dec 31, 2024 | -208,000.00 |
| Sep 30, 2024 | -113,000.00 |
| Sep 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | -193,000.00 |
| Sep 30, 2023 | -193,000.00 |